Last reviewed · How we verify
Antiarrhythmic Drug Therapy
At a glance
| Generic name | Antiarrhythmic Drug Therapy |
|---|---|
| Also known as | Betapace (sotalol), Mexitil (mexiletine), Pronestyl (procainamide), Cordarone (amiodarone), amiodarone, sotalol, class III antiarrhyhtmic agents, Class I or III antiarrhythmic drug |
| Sponsor | IRCCS San Raffaele |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies (NA)
- Acupuncture for Preventing Atrial Arrhythmia Recurrence After Ablation (NA)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (NA)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation (NA)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiarrhythmic Drug Therapy CI brief — competitive landscape report
- Antiarrhythmic Drug Therapy updates RSS · CI watch RSS
- IRCCS San Raffaele portfolio CI